Fennec Pharmaceuticals markets Pedmark to reduce cisplatin-induced ototoxicity in pediatric patients but faces challenges in adoption. FENC has missed financial projections, with revenues below ...

Fennec Pharmaceuticals (NASDAQ:FENC) (the Company), is a small cap, commercial-stage biotech company with a single drug, PEDMARK®. PEDMARK is a unique formulation of sodium thiosulfate ...

Children undergoing cancer treatment now have a drug alternative. The FDA has given the regulatory green light to a Fennec Pharmaceuticals drug that reduces the risk of hearing loss in patients ...

RESEARCH TRIANGLE PARK, N.C., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a commercial stage specialty pharmaceutical ...

RESEARCH TRIANGLE PARK, N.C., Aug. 22, 2022 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today ...

With one drug in its pipeline, 26-year-old Fennec Pharmaceuticals of North Carolina has had a lot riding on its treatment for chemotherapy-induced hearing loss. Finally, 18 years after it was ...